Literature DB >> 28104813

Structural modeling defines transmembrane residues in ADAM17 that are crucial for Rhbdf2-ADAM17-dependent proteolysis.

Xue Li1,2, Thorsten Maretzky1, Jose Manuel Perez-Aguilar3,4, Sébastien Monette5, Gisela Weskamp1, Sylvain Le Gall1, Bruce Beutler6, Harel Weinstein3, Carl P Blobel7,2,3,8.   

Abstract

A disintegrin and metalloproteinase 17 (ADAM17) controls the release of the pro-inflammatory cytokine tumor necrosis factor α (TNFα, also known as TNF) and is crucial for protecting the skin and intestinal barrier by proteolytic activation of epidermal growth factor receptor (EGFR) ligands. The seven-membrane-spanning protein called inactive rhomboid 2 (Rhbdf2; also known as iRhom2) is required for ADAM17-dependent TNFα shedding and crosstalk with the EGFR, and a point mutation (known as sinecure, sin) in the first transmembrane domain (TMD) of Rhbdf2 (Rhbdf2sin) blocks TNFα shedding, yet little is known about the underlying mechanism. Here, we used a structure-function analysis informed by structural modeling to evaluate the interaction between the TMD of ADAM17 and the first TMD of Rhbdf2, and the role of this interaction in Rhbdf2-ADAM17-dependent shedding. Moreover, we show that double mutant mice that are homozygous for Rhbdf2sin/sin and lack Rhbdf1 closely resemble Rhbdf1/2-/- double knockout mice, highlighting the severe functional impact of the Rhbdf2sin/sin mutation on ADAM17 during mouse development. Taken together, these findings provide new mechanistic and conceptual insights into the critical role of the TMDs of ADAM17 and Rhbdf2 in the regulation of the ADAM17 and EGFR, and ADAM17 and TNFα signaling pathways.
© 2017. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  ADAM17; EGF receptor; Rhbdf2; TACE; iRhom2

Mesh:

Substances:

Year:  2017        PMID: 28104813      PMCID: PMC5358332          DOI: 10.1242/jcs.196436

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  47 in total

Review 1.  ADAMs: key components in EGFR signalling and development.

Authors:  Carl P Blobel
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

2.  Crystal structure of a rhomboid family intramembrane protease.

Authors:  Yongcheng Wang; Yingjiu Zhang; Ya Ha
Journal:  Nature       Date:  2006-10-11       Impact factor: 49.962

Review 3.  Ectodomain shedding and ADAMs in development.

Authors:  Silvio Weber; Paul Saftig
Journal:  Development       Date:  2012-10       Impact factor: 6.868

4.  Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17.

Authors:  Thorsten Maretzky; Astrid Evers; Wenhui Zhou; Steven L Swendeman; Pui-Mun Wong; Shahin Rafii; Karina Reiss; Carl P Blobel
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

5.  iRHOM2 is a critical pathogenic mediator of inflammatory arthritis.

Authors:  Priya Darshinee A Issuree; Thorsten Maretzky; David R McIlwain; Sébastien Monette; Xiaoping Qing; Philipp A Lang; Steven L Swendeman; Kyung-Hyun Park-Min; Nikolaus Binder; George D Kalliolias; Anna Yarilina; Keisuke Horiuchi; Lionel B Ivashkiv; Tak W Mak; Jane E Salmon; Carl P Blobel
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

6.  An essential role for ectodomain shedding in mammalian development.

Authors:  J J Peschon; J L Slack; P Reddy; K L Stocking; S W Sunnarborg; D C Lee; W E Russell; B J Castner; R S Johnson; J N Fitzner; R W Boyce; N Nelson; C J Kozlosky; M F Wolfson; C T Rauch; D P Cerretti; R J Paxton; C J March; R A Black
Journal:  Science       Date:  1998-11-13       Impact factor: 47.728

7.  ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha.

Authors:  Sylvain M Le Gall; Pierre Bobé; Karina Reiss; Keisuke Horiuchi; Xiao-Da Niu; Daniel Lundell; David R Gibb; Daniel Conrad; Paul Saftig; Carl P Blobel
Journal:  Mol Biol Cell       Date:  2009-01-21       Impact factor: 4.138

8.  Inflammatory skin and bowel disease linked to ADAM17 deletion.

Authors:  Diana C Blaydon; Paolo Biancheri; Wei-Li Di; Vincent Plagnol; Rita M Cabral; Matthew A Brooke; David A van Heel; Franz Ruschendorf; Mark Toynbee; Amanda Walne; Edel A O'Toole; Joanne E Martin; Keith Lindley; Tom Vulliamy; Dominic J Abrams; Thomas T MacDonald; John I Harper; David P Kelsell
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

9.  Phosphatidylserine exposure is required for ADAM17 sheddase function.

Authors:  Anselm Sommer; Felix Kordowski; Joscha Büch; Thorsten Maretzky; Astrid Evers; Jörg Andrä; Stefan Düsterhöft; Matthias Michalek; Inken Lorenzen; Prasath Somasundaram; Andreas Tholey; Frank D Sönnichsen; Karl Kunzelmann; Lena Heinbockel; Christian Nehls; Thomas Gutsmann; Joachim Grötzinger; Sucharit Bhakdi; Karina Reiss
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

10.  Epidermal EGFR controls cutaneous host defense and prevents inflammation.

Authors:  Beate M Lichtenberger; Peter A Gerber; Martin Holcmann; Bettina A Buhren; Nicole Amberg; Viktoria Smolle; Holger Schrumpf; Edwin Boelke; Parinaz Ansari; Colin Mackenzie; Andreas Wollenberg; Andreas Kislat; Jens W Fischer; Katharina Röck; Jürgen Harder; Jens M Schröder; Bernhard Homey; Maria Sibilia
Journal:  Sci Transl Med       Date:  2013-08-21       Impact factor: 17.956

View more
  15 in total

1.  Substrate-selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains.

Authors:  Beiyu Tang; Xue Li; Thorsten Maretzky; Jose Manuel Perez-Aguilar; David McIlwain; Yifang Xie; Yufang Zheng; Tak W Mak; Harel Weinstein; Carl P Blobel
Journal:  FASEB J       Date:  2020-02-26       Impact factor: 5.191

2.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

3.  ADAM17 stabilizes its interacting partner inactive Rhomboid 2 (iRhom2) but not inactive Rhomboid 1 (iRhom1).

Authors:  Gisela Weskamp; Johanna Tüshaus; Daniel Li; Regina Feederle; Thorsten Maretzky; Steven Swendemann; Erik Falck-Pedersen; David R McIlwain; Tak W Mak; Jane E Salmon; Stefan F Lichtenthaler; Carl P Blobel
Journal:  J Biol Chem       Date:  2020-02-14       Impact factor: 5.157

4.  Targeted truncation of the ADAM17 cytoplasmic domain in mice results in protein destabilization and a hypomorphic phenotype.

Authors:  Jose Lora; Gisela Weskamp; Thomas M Li; Thorsten Maretzky; Dorjee T N Shola; Sébastien Monette; Stefan F Lichtenthaler; Theresa T Lu; Chingwen Yang; Carl P Blobel
Journal:  J Biol Chem       Date:  2021-05-03       Impact factor: 5.157

5.  The iRhom homology domain is indispensable for ADAM17-mediated TNFα and EGF receptor ligand release.

Authors:  Stefan Düsterhöft; Selcan Kahveci-Türköz; Justyna Wozniak; Anke Seifert; Petr Kasparek; Henrike Ohm; Shixin Liu; Jana Kopkanova; Juliane Lokau; Christoph Garbers; Christian Preisinger; Radislav Sedlacek; Matthew Freeman; Andreas Ludwig
Journal:  Cell Mol Life Sci       Date:  2021-05-05       Impact factor: 9.261

6.  Phosphorylation of iRhom2 Controls Stimulated Proteolytic Shedding by the Metalloprotease ADAM17/TACE.

Authors:  Miguel Cavadas; Ioanna Oikonomidi; Catarina J Gaspar; Emma Burbridge; Marina Badenes; Inês Félix; Alfonso Bolado; Tianyi Hu; Andrea Bileck; Christopher Gerner; Pedro M Domingos; Alex von Kriegsheim; Colin Adrain
Journal:  Cell Rep       Date:  2017-10-17       Impact factor: 9.423

7.  The molecular, cellular and pathophysiological roles of iRhom pseudoproteases.

Authors:  Iqbal Dulloo; Sonia Muliyil; Matthew Freeman
Journal:  Open Biol       Date:  2019-03-29       Impact factor: 6.411

8.  Mutagenesis of the ADAM17-phosphatidylserine-binding motif leads to embryonic lethality in mice.

Authors:  Martin Veit; Björn Ahrens; Jana Seidel; Anselm Sommer; Sucharit Bhakdi; Karina Reiss
Journal:  Life Sci Alliance       Date:  2019-08-27

9.  Role of iRhoms 1 and 2 in Endochondral Ossification.

Authors:  Renpeng Fang; Coline Haxaire; Miguel Otero; Samantha Lessard; Gisela Weskamp; David R McIlwain; Tak W Mak; Stefan F Lichtenthaler; Carl P Blobel
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 5.923

Review 10.  iRhom2: An Emerging Adaptor Regulating Immunity and Disease.

Authors:  Mazin A Al-Salihi; Philipp A Lang
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.